Basic information Safety Supplier Related

Pertuzumab

Basic information Safety Supplier Related

Pertuzumab Basic information

Product Name:
Pertuzumab
Synonyms:
  • pertuzumab
  • 2C4
  • Immunoglobulin G1, anti-(human V (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 kappa-chain, dimer
  • Omnitarg
  • Unii-K16aiq8ctm
  • Pertuzumab (anti-HER2)
  • Pertuzumab-Perjeta
  • Research Grade Pertuzumab(DHC09602)
CAS:
380610-27-5
MF:
C17H27NO2
MW:
277.40178
Mol File:
380610-27-5.mol
More
Less

Pertuzumab Chemical Properties

form 
Liquid
color 
Colorless to light yellow
More
Less

Safety Information

Hazardous Substances Data
380610-27-5(Hazardous Substances Data)
More
Less

Pertuzumab Usage And Synthesis

Description

Pertuzumab is an anti-human epidermal growth factor receptor 2 (HER2) antibody that was approved by the US FDA in June 2012 for use in combination with trastuzumab (Herceptin?) and docetaxel chemotherapy for the treatment of people with HER2-positive (HER2+) metastatic breast cancer (mBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Pertuzumab inhibits HER2 dimer formation with other HER members, such as HER1 and HER3, thus inhibiting the downstream signaling processes associated with tumor growth and progression. Pertuzumab is the first HER2 dimerization inhibitor to reach the market. The mechanism of actions of trastuzumab and pertuzumab are believed to complement each other and provide a more comprehensive inhibition of tumor growth than either agent alone. Preclinical data showed that the combination of trastuzumab and pertuzumab has a strongly enhanced antitumor effect and induces tumor regression in xenograft models, something that cannot be achieved by either monotherapy alone.

Originator

Genentech, a member of the Roche Group (United States)

Uses

Anti-neoplastic.

brand name

Perjeta

Clinical Use

Monoclonal antibody:
Treatment of HER2 receptor +ve breast cancer

Metabolism

Antibodies are cleared mainly by catabolism.

PertuzumabSupplier

Wuhan Sunrise Technology Development Co., Ltd.
Tel
27-027-83314682 13554138826
Email
whsrtech@vip.163.com
Wuhan Fortuna Chemical Co., Ltd
Tel
027-59207852 13308628970
Email
buy@fortunachem.com
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
meilunui@163.com
Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Email
waley188@sohu.com
Nanjing Sunlida Biological Technology Co., Ltd.
Tel
025-57798810
Email
sales@sunlidabio.com